Subscribe to RSS
DOI: 10.1055/s-2003-45496
© Georg Thieme Verlag Stuttgart · New York
Methylenetetrahydrofolate Reductase Gene Polymorphism and Glucocorticoid Intake in Children with ALL and Aseptic Osteonecrosis
Methylentetrahydrofolat-Reduktase-Gen-Polymorphismus und Glukokortikoid-Behandlung bei Kindern mit ALL und aseptischer OsteonekrosePublication History
Publication Date:
15 December 2003 (online)
![](https://www.thieme-connect.de/media/klinpaed/200306/lookinside/thumbnails/10.1055-s-2003-45496-1.jpg)
Zusammenfassung
Hintergrund: Methotrexat ist essenzieller Bestandteil der Behandlung der akuten lymphoblastischen Leukämie (ALL). Aufgrund guten Langzeitüberlebens der Patienten gewinnen die Spätfolgen der Behandlung wie BME (bone marrow edema) und AON (aseptic osteonecrosis) zunehmend an Interesse. Ziel der Untersuchung war es, herauszufinden, ob ein Polymorphismus des Methylentetrahydrofolsäure-Reduktase-(MTHFR)-Gens prädisponierend für die Entstehung von BME und/oder AON ist. Zusätzlich wurde die kumulativ verabreichte Prednisondosis dieser Patienten errechnet und in einer Matched-pairs-Analyse verglichen. Patienten und Methoden: 87 Patienten wurden retrospektiv auf einen MTHFR-Polymorphismus hin untersucht (48 männlich, 43 weiblich). Bei 14/87 Patienten waren ein BME und/oder eine AON diagnostiziert worden (16 %). Ergebnisse: 42/73 Patienten ohne BME und/oder AON (43 männlich, 34 weiblich, mittleres Alter 5,3 Jahre) sowie 10/14 der Patienten mit BME/AON (5 männlich, 9 weiblich, mittleres Alter 10,2 Jahre) wiesen einen MTHFR-Polymorphismus auf (p = 0.28). 14,3 % der Patienten mit MTHFR-Polymorphismus aber ohne BME und/oder AON (6/42) und 70 % der Patienten mit MTHFR-Polymorphismus und mit BME und/oder AON (7/10) waren über 10 Jahre bei ALL-Diagnose (p = 0,002). Die mittlere kumulativ verabreichte Menge an Prednison betrug in einer Matched-pairs-Analyse 98,0 mg/kg KG respektive 100,0 mg/kg KG. Schlussfolgerung: Das Alter der Patienten bei ALL-Diagnose scheint einen Risikofaktor für die Entstehung von BME und/oder AON darzustellen, was auch durch voran gegangene Untersuchungen bestätigt wird. Weiterhin ergibt sich der Hinweis auf einen Zusammenhang zwischen dem MTHFR-Polymorphismus und der Entstehung von BME/AON. Dieser Aspekt ist wert, an einer größeren Fallzahl unter Berücksichtigung der MTX-Pharmakokinetik und der Leukovorin-Rescue überprüft zu werden.
Abstract
Backround: Methotrexate is an essential part of the treatment of acute lymphoblastic leukaemia (ALL). Due to an increased survival of ALL patients, complications like BME (bone marrow edema) and AON (aseptic osteonecrosis) have become a matter of increasing importance. The aim of the study was to find out if a polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene predisposes to the development of BME and/or AON. Furthermore the cumulative prednisone equivalent dose per kilogram body weight was compared in a matched-pairs analysis. Patients and methods: A retrospective analysis of the MTHFR polymorphism of 87 patients was performed (48 male, 43 female). 14/87 patients were diagnosed with BME and/or AON (16 %). Results: 42/73 patients without BME and/or AON (43 male, 34 female, median age 5.3 yrs) and 10/14 patients with BME/AON (5 male, 9 female, median age 10.2 years) presented with a MTHFR-polymorphism (p = 0.28). 14,3 % of the patients with MTHFR-polymorphism but without BME and/or AON (6/42) and 70 % of the patients with MTHFR-polymorphism and with BME and/or AON (7/10) were over 10 years of age at ALL diagnosis (p = 0.002). The mean cumulative prednisone equivalent dose per kilogram body weight was 98.0 mg, compared with 100.0 mg in the matched pairs group. Conclusions: The age of the patients at diagnosis seems to be a risk factor for the development of BME and/or AON as also seen in previous studies. If MTHFR polymorphism is an additional risk factor it was not borne out by this study, possible due to the small number of patients analyzed. This aspect is worth to be proven with a large group of patients considering the MTX pharmacokinetic and leucovorine rescue.
Schlüsselwörter
MTHFR-Polymorphismus - Knochenmarksödem - Aseptische Osteonekrosen - Glukokortikoide - ALL
Key words
MTHFR-polymorphism - bone marrow edema - aseptic osteonecrosis - glucocorticoids - ALL
References
- 1 Arruda V R, von Zuben P M, Chiaparini L C, Annichino-Bizzachi J M, Costa F F. The mutation Ala677→Val in the methylene tetrahydorfolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost. 1997; 77 818-812
- 2 Barr R D, Halton J, Willan A, Cockshott W P, Gill G, Atkinson S. Impact of age and cranial irradiation on radiographic skeletal pathology in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1998; 30 347-350
- 3 Bernbeck B, Krauth K A, Scherer A, Engelbrecht V, Göbel U. Aseptic osteonecrosis in a child with nephroblastoma healed by hyperbaric oxygen therapy. Med Pediatr Oncol. 2002; 39 47-48
- 4 Boushey C J, Beresford S AA, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995; 274 1049-1057
- 5 Frosst P, Blom H J, Milos R, Goyette P, Sheppard C A, Matthews R G, Boers G J, den Heijer M, Kluijtmans L A, van den Heuvel L P, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10 111-113
- 6 Harms D O, Janka-Schaub G E. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia. 2000; 14 2234-2239
- 7 Heijer M, Keijzer M. Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem Lab Med. 2001; 39 710-713
- 8 Janka-Schaub G E, Harms D O, den Boer M L, Veerman A J, Pieters R. In vitro drug resistance as independent prognostic factor in the study COALL-O5 - 92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06 - 97. Klin Padiatr. 1999; 211 233-238
- 9 Jones J P. Fat embolism, intravascular coagulation, and osteonecrosis. Clin Orthop. 1993; 292 294-308
- 10 Kechli A, Wiliams J, Pui C H, Park V, Tonkel S, Deitcher S R. Factor V Leiden and other hypercoagulable state mutations are not associated with osteonecrosis during or after treatment for pediatric malignancy. J Pediatr. 1999; 134 310-314
- 11 Kirschke R, Nurnberger W, Eckhof-Donovan S, Nürnberger I, Göbel U. Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05 - 92-protocol. Klin Padiatr. 1998; 210 285-290
- 12 Koch H G, Nabel P, Junker R, Auberger K, Schobess R, Homberger A, Linnebank M, Nowak-Göttl U. The 667T genotype of the common MTHFR thermolabile variant and fasting homocysteine in childhood venous thrombosis. Eur J Pediatr. 1999; 158(Suppl3) (Suppl 3) 113-116
- 13 Körholz D, Bruder M D, Engelbrecht V, Rüther W, Göbel U. Aseptic osteonecrosis in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1998; 15 307-315
- 14 Mattano L A, Sather H N, Trigg M E, Nachmann J B. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the children’s cancer group. J Clin Oncol. 2000; 18 3262-3272
- 15 Mauz-Körholz C, Nürnberger W, Irsfeld H, Körholz D, Göbel U. Low rate of severe venous thromboses in children with ALL treatment according to CoALL-5 - 92 and -97 protocol. Klin Pädiatr. 1999; 211 215-217
- 16 Mauz-Körholz C, Junker R, Göbel U, Nowak-Göttl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (CoALL-92 and 97 protocols). Thromb Haemos. 2000; 83 840-843
- 17 Nowak-Göttl U, Wermes C, Junker R, Koch H G, Schobess R, Fleischhack G, Schwabe D, Ehrenforth S. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 1999; 93 1595-1599
- 18 Ojala A E, Lanning F P, Paakko E, Lanning B M. Osteonecrosis in children treated for acute lymphoblastic leukemia: a magnetic resonance imaging study after treatment. Med Pediatr Oncol. 1997; 29 260-265
- 19 Ojala A E, Paakko E, Lanning F P, Lanning M. Osteonecrosis during the treatment of childhood acute lymphoblastic leukemia: a prospective MRI study. Med Pediatr Oncol. 1999; 32 11-17
- 20 Preston S J, Diamond T, Scott A, Laurent M R. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis. 1993; 52 582-585
- 21 Raab P, Kühl J, Krauspe R. Multifokale Osteonekrosen bei Kindern und Jugendlichen nach Polychemotherapie. Z Orthop. 1997; 135 444-450
- 22 Schnyder G, Roffi M, Pin M, Flammer Y, Lange H, Eberli F R, Meier B, Turi Z G, Hess O M. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001; 345 1593-1600
- 23 Schwartz A M, Leonidas J C. Methotrexate osteopathy. Skeletal Radiol. 1984; 11 13-16
- 24 Semeraro N, Montemurro P, Giordano P, Schettini F, Santoro N, de Mattia D, Giordano D, Conese M, Colucci M. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia. Thromb Haemost. 1990; 64 38-40
- 25 Stehouwer C DA, Jakobs C. Abnormalities for vascular function in hyperhomocysteineaemia: relationship to atherothrombotic disease. Eur J Pediatr. 1998; 157 (Suppl 2) S107-S111
- 26 Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, Mini E, Boiocchi M. Effect of methylenetetrahydrofolate reductase 677C->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer. 2003; 103 294-299
- 27 Ueland P M, Hustad S, Schneede J, Refsum H, Vollset S E. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001; 22 195-201
- 28 Wang G J, Sweet D E, Reger S I, Thompson R C. Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J Bone Joint Surg. 1977; 59 729-735
Benedikt Bernbeck, MD
Department of Paediatric Oncology, Haematology and Immunology; Children’s Hospital, Heinrich-Heine-University, Medical Center
Moorenstr. 5
40225 Düsseldorf, Germany
Phone: +49/211/811 9108
Fax: +49/211/811 6038
Email: bernbeck@med.uni-duesseldorf.de